InMed Pharmaceuticals regains Nasdaq compliance after stock price recovery

InMed Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share after its stock traded at or above that level for 10 consecutive business days. The company had been notified of non-compliance on March 27, 2026, but successfully remedied the listing deficiency.